PASI (Psoriasis Area and Severity Index)
Psoriasis Area and Severity Index · Also known as: PASI Index
The PASI is the gold-standard clinician-administered measure of psoriasis severity and extent. Developed by Fredriksson and Pettersson in 1978, it evaluates four cardinal clinical signs (erythema, induration, desquamation) across four body regions, each weighted by anatomical importance. PASI is the most widely used endpoint in psoriasis clinical trials and is endorsed by regulatory agencies (FDA, EMA) and international dermatology societies.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
PASI is mandatory in all phase 2b–3 clinical trials of psoriasis treatments and is the standard measurement in specialist dermatology clinics for patients with moderate-to-severe disease. It is recommended for baseline documentation and periodic re-assessment (every 4–12 weeks) during systemic therapy. PASI is less practical in primary care due to time demands and the need for dermatology expertise. For mild disease confined to specific sites (scalp, nails, palms), PASI may underestimate burden; supplementary measures (Nail Psoriasis Severity Index, Scalp Psoriasis Severity Index) are used adjunctively.
Strengths & limitations
- Internationally validated and standardized; endorsed by FDA, EMA, and all major dermatology societies.
- Highly responsive to treatment; capable of detecting meaningful change across broad therapeutic interventions.
- Regional weighting reflects clinical priorities; facial and hand involvement carry higher weight, aligning with patient-centered outcomes.
- Detailed granular assessment of sign intensity enables tracking of specific phenotypic changes (e.g., erythema may resolve before desquamation).
- Widely used in historical trials, allowing cross-study comparisons and evidence synthesis.
- Clear severity thresholds and response criteria facilitate communication among clinicians and researchers.
- Requires trained clinician assessment; not suitable for patient self-administration or remote evaluation.
- Time-consuming; 10–20 minutes, limiting feasibility in busy primary care practices.
- Area estimation is subjective; inter-rater agreement for percentage affected is only moderate, particularly for mid-range estimates (30–70%).
- Sign grading (especially induration and desquamation distinction) can be ambiguous and training-dependent.
- May underestimate total disease burden in patients with widespread mild disease; poorly sensitive to diffuse erythema without induration.
- Does not capture invisible symptoms (pruritus, pain) or quality-of-life impact; purely objective measure.
Frequently asked
What is PASI-75 and why is it the standard trial endpoint?
PASI-75 means a 75% reduction in PASI score from baseline to a specified timepoint (typically Week 12 or Week 16). It was chosen as the regulatory standard because it represents clinically meaningful improvement and is achievable by most patients on active systemic therapies, yet is selective enough to differentiate active treatments from placebo. PASI-75 is now mandated in FDA and EMA guidance documents.
How is PASI different from the area-only severity scale?
PASI evaluates both extent (percentage area affected) and intensity (erythema, induration, desquamation); area-only scales measure only the percentage of involved skin. PASI is superior because a 50% improvement in redness and plaque thickness (without change in area) is clinically meaningful and will be detected by PASI but not by area-alone measures.
Should PASI be combined with patient-reported outcomes?
Yes. PASI is purely clinician-observed and does not capture pruritus, pain, or quality-of-life impact. Modern trials increasingly combine PASI with patient-reported outcomes (PRO) such as the Dermatology Life Quality Index (DLQI) or itch numeric rating scale (NRS) to provide a more complete efficacy picture.
What is the MCID (minimal clinically important difference) for PASI?
The absolute MCID for PASI has not been formally established. However, PASI-50 (50% reduction) is considered meaningful improvement, and PASI-75 is considered significant response. In clinical practice, a reduction of ≥3–5 PASI points may be clinically detectable, but always report percentage change from baseline in addition to absolute change.
How should PASI be adapted for patients with predominantly scalp or nail psoriasis?
PASI underestimates burden in patients with limited body surface area involvement or non-plaque morphologies. Supplementary measures are recommended: Scalp Psoriasis Severity Index (SPSI) for scalp disease, Nail Psoriasis Severity Index (NAPSI) for nail involvement, and Palmoplantar Psoriasis Severity Index (PPSI) for palmar and plantar disease. Use these in conjunction with PASI for comprehensive assessment.
Sources
- Fredriksson T, Pettersson U. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-244. DOI: 10.1159/000250839 ↗
- Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(Suppl 2):ii65-ii68. DOI: 10.1136/ard.2004.031237 ↗
How to cite this page
ScholarGate. (2026, June 3). Psoriasis Area and Severity Index. ScholarGate. https://scholargate.app/en/dermatology/pasi
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
Compare side by side →